Phase 3 study of subcutaneous versus intravenous tislelizumab plus chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma

Phase 3, randomised, open-label trial of tislelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by BeiGene. Primary endpoints: Model-predicted steady-state serum trough concentration (Ctrough) before dosing on Cycle 5 Day 1 and Model-predicted serum concentration-time area under the curve from 0 to 21 days after first dose in Cycle 1 (AUC0-21d). Started Aug 2025; status: active.